Medicare reverses course on pricey new cancer drug

(By – Robert Pear, New York Times)

The Obama administration has decided Medicare will pay for one of the newest, most expensive cancer medications, which costs about $178,000 for a standard course of treatment. Patients, doctors, hospital executives and insurers have expressed concern about the high cost of prescription drugs, especially new cancer medicines and treatments tailored to the genetic characteristics of individual patients. Read more…

 

Notice: The “Read more…” link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.